Vector Capital to Acquire Showpad
Vector Capital Management, L.P., a leading private equity firm specializing in transformational investments in established technology businesses, today announced an agreement to acquire Showpad, a leader in AI revenue enablement technology with headquarters in Chicago and Ghent, Belgium.
Customers in over 50 countries —including Coca-Cola, Dow, DuPont, GE Healthcare, Kaiser Permanente and Schneider Electric — leverage Showpad to bring together marketing and revenue teams to engage buyers and add value at every interaction. The company is a Forrester Wave™ leader in multiple categories2, and a “Customers’ Choice” for Revenue Enablement Platforms3 on Gartner® Peer Insights™.
After the transaction closes, Vector will combine Showpad with Bigtincan Holdings, which it acquired in April 2025. The combined entity will operate under the Showpad brand. It will deliver a complete AI-powered revenue enablement solution across all aspects of buyer-seller engagement with broad geographic diversity, and combined R&D resources to accelerate innovation market-wide.
Bigtincan is a five-time leader in The Aragon Research Globe™for Sales Enablement Platforms and has received multiple awards for AI and other innovations. Over 1,000 companies — including Abbott, AT&T, Clorox, Merck, Winnebago, and 100 of the Fortune 500 — use Bigtincan’s AI-powered sales enablement solutions to augment, automate and modernize seller and buyer engagement.
“The combination of Bigtincan with Showpad brings together best-in-class innovation and market leaders with thousands of customers,” said Amish Mehta, Chief Investment Officer and Managing Director at Vector Capital. “The combined company will lead the digital and AI-fueled buyer and seller engagement and drive a new generation of experiences that people and brands love.”
Insight Partners, a large investor in Showpad, will roll over its full investment into the combined company. The completion of the transaction is subject to customary conditions, including regulatory approval. Further terms were not disclosed, and the transaction is expected to close in 2025.
Watershed Moment in AI-Powered Revenue Enablement Market
“The merger of Showpad and Bigtincan represents a watershed moment for the sales enablement market,” said Jim Lundy, Founder and Lead Analyst at Aragon Research. “By uniting complementary strengths in content, readiness, and AI, the combined company is poised to deliver on the market's unmet demand for AI-centric sales enablement platforms that are easier to deploy, simpler to use and more impactful for revenue teams worldwide."
“Our unwavering focus on driving success for customers fueled a record-breaking year of growth for Showpad in 2024,” said Hendrik Isebaert, CEO of Showpad. “Together we will deliver a breadth of flexible solutions and an incredible team to help customers engage with buyers in new and creative ways they never thought possible.”
“Evolving preferences and rapid technology advancements are aggressively transforming buying and selling behaviors,” said Jim Hopkins, Chairman of Bigtincan. “We invested early and heavily in AI, and our combined global R&D resources will accelerate innovation so customers can rapidly reap the benefits of AI and emerging future innovations.”
Sidley Austin LLP is serving as legal counsel, Deloitte LLP is serving as tax advisor and Alvarez & Marsal is serving as financial advisor to Vector Capital. Cleary Gottlieb Steen & Hamilton LLP is acting as legal counsel and TD Securities is acting as financial advisor to Showpad.
“Vector Capital has a long history of building category-defining technology companies,” said Rob Amen, Managing Director at Vector Capital. “Both companies bring impressive industry expertise and commitment to excellence. Together, they will continue to drive the future and set industry standards and best practices globally.”
For more, visit our acquisition information page and follow Bigtincan, Showpad and Vector Capital on LinkedIn.
About Vector Capital Management, L.P.
Vector Capital is a leading San Francisco-based investment firm focused on transformational investments in middle-market technology and technology-enabled businesses. Founded in 1997, Vector manages over $4 billion of capital across credit and private equity strategies on behalf of a high-quality group of global limited partners. For nearly 28 years, Vector has combined technology investments with operational transformation to deliver breakthrough results. For more information, visit www.vectorcapital.com.
1 Grand View Research, Sales Enablement Platform Market Size Report, 2030. | |
2 Forrester Wave™: Revenue Enablement Platforms, Q3 2024, and Sales Readiness Solutions, Q4 2023 reports. | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250826870353/en/
Contacts
Bryan Scanlon
Look Left Marketing
vector@lookleftmarketing.com
+1 (925) 759-3265
Vector Capital:
Nathaniel Garnick / Grace Cartwright
Gasthalter & Co.
+1 (212) 257-4170 - vector@gasthalter.com
Showpad:
Moon Kang
+2 (804) 601-0583
moon.kang@showpad.com
Bigtincan:
Denise Iverson
+1 (214) 509-8557
denise.iverson@bigtincan.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release
Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom